Putative new childhood leukemia cancer predisposition syndrome caused by germline bi-allelic missense mutations in DDX41

Genes, Chromosomes & Cancer
Birgitte R DinessKarin A W Wadt

Abstract

DDX41 has recently been identified as a new autosomal dominantly inherited cancer predisposition syndrome causing increased risk of adult onset acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We report for the first time compound heterozygote germline missense DDX41 mutations located in the DEAD-box domain, identified in two siblings by exome sequencing. Both siblings have slight dysmorphic findings, psychomotor delays and intellectual disability, and one developed blastic plasmacytoid dendritic cell neoplasm (BPDCN) at age five. RNA-sequencing of bone marrow showed DDX41 expression including both mutations. However, the allele fraction of p.Pro321Leu accounted for 96% in the RNA-sequencing indicating this mutation to be the more significant variant. Exome sequencing of the leukemic blasts identified no additional known driver mutations. There is no pattern indicating autosomal dominantly inherited cancer predisposition in the family, but the father has sarcoidosis, which has been associated with heterozygous DDX41 mutation. We propose that bi-allelic mutations in DDX41 could potentially be a new cancer predisposition syndrome associated with delayed psychomotor development.

References

Jun 18, 2002·Science·Niall G HowlettAlan D D'Andrea
Aug 30, 2002·British Journal of Haematology·Ray A CartwrightAnthony V Moorman
Jun 8, 2012·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Fanny Angelot-DelettreFrancine Garnache-Ottou
Apr 17, 2014·Journal of Medical Genetics·Katharina WimmerUNKNOWN EU-Consortium Care for CMMRD (C4CMMRD)
Apr 30, 2015·Cancer Cell·Chantana PolprasertJaroslaw P Maciejewski
Sep 15, 2016·Nature·Mary E DickinsonStephen A Murray
Dec 9, 2016·Protein & Cell·Yan JiangSongying Ouyang
Mar 30, 2017·The Journal of Biological Chemistry·Dominik PetersReiner U Jänicke
May 27, 2017·International Journal of Hematology·Jesse J C CheahAnna L Brown
Sep 1, 2017·Molecular and Clinical Oncology·Wenjun DengLiangchun Yang
Sep 15, 2017·Journal of Pediatric Hematology/oncology·Marie Jeong-Min KimDina El Demellawy

❮ Previous
Next ❯

Citations

Jun 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kayla V HamiltonKim E Nichols
Jun 9, 2020·Frontiers in Genetics·Dustin B Miller, Stephen R Piccolo
Apr 9, 2021·Frontiers in Genetics·Dustin B Miller, Stephen R Piccolo

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.